Hepatocellular carcinoma (HCC) is a common malignant cancer worldwide and the third leading cause of cancer death.^1,2 Surgical resection followed by liver transplantation is a curative treatment for early stage HCC, but the tumor is prone to recurrence.³ Furthermore, the clinical symptoms of early stage HCC are frequently unclear, and diagnosis may be delayed until an advanced stage, resulting in a high mortality rate.⁴ Sorafenib, a multikinase inhibitor, is used as first-line treatment for patients with advanced-stage HCC, but may only provide a three-month survival benefit in comparison with a placebo.⁵ Thus, establishment of new chemotherapy is urgently needed, especially for patients with advanced HCC.

中文翻译：

---

AR420626 是 GPR41/FFA3 的选择性激动剂，通过抑制 HDAC 诱导细胞凋亡来抑制肝细胞癌细胞的生长

肝细胞癌（HCC）是世界范围内常见的恶性肿瘤，也是癌症死亡的第三大原因。^1,2手术切除后肝移植是早期 HCC 的治愈性治疗方法，但肿瘤容易复发。³此外，早期 HCC 的临床症状往往不明确，诊断可能会延迟到晚期，导致高死亡率。⁴索拉非尼是一种多激酶抑制剂，被用作晚期 HCC 患者的一线治疗，但与安慰剂相比，可能仅能提供三个月的生存获益。⁵因此，迫切需要建立新的化疗方案，尤其是对于晚期 HCC 患者。